Pulmatrix's CEO Eyes $25 Billion COPD Market for Its Inhaled Drug Delivery Technology

Press Release (ePRNews.com) - New York, NY - Jun 06, 2016 -  Stock-­Sector.com, ​an online source of news about promising medical, technology and energy companies, today released an ​interview​ with ​Robert Clarke, PhD​, CEO of Pulmatrix.

In the interview, Dr. Clarke describes the history of Pulmatrix, and explains why the company technology and pipeline offers “an obvious value proposition” for investors.

“affects tens of millions of patients, with an over $25 billion market”

Robert Clarke PhD, CEO Pulmatrix

Trained as a biomedical engineer with a PhD in pulmonary physiology, Dr. Clarke has worked on inhaled drug delivery for about 20 years. His initial research led to an aerosol that, when inhaled, reduced the chances that a person would spread respiratory diseases to others. More important, it also had a therapeutic, anti-inflammatory effect.

Pulmatrix began to develop that aerosol to help treat chronic pulmonary obstructive disease (COPD). But ​Dr. Clarke realized ​that a dry powder formulation would work even better. As a company with a high percentage of engineers, “we had the expertise to transfer from aerosol to dry powder,” he explains. “This novel technology we call iSPERSE allows us to deliver drugs more efficiently.”

The company now has an extensive pipeline ​of inhaled drug candidates that reveal the “real value” of Pulmatrix, Dr. Clarke says. The lead program is for ​COPD​, “which affects tens of millions of patients, with an over $25 billion market,” Dr. Clarke explains. If an ongoing analysis of clinical data shows the expected results, it could trigger a licensing agreement with a major pharma partner, with a fast track to approval in Europe. “It can go very rapidly,” he says.

Next in the pipeline are inhaled drug candidates to fight lung infections and idiopathic pulmonary fibrosis. Each one could be either developed with a partner or by Pulmatrix on its own. “The further we go ourselves, the greater the value proposition for Pulmatrix,” Dr. Clarke says in the interview.

In addition, the pipeline will continue to grow. “We are thinking about novel therapeutics we can enable with our technology,” Dr. Clarke says.


Source : Stock-Sector.com, info@stock-sector.com
Business Info :

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.